Generic Name and Formulations:
Cetrorelix (as acetate) 0.25mg, 3mg; per vial; pwd for SC inj after reconstitution.
EMD Serono, Inc.
Indications for CETROTIDE:
Inhibition of premature LH surges in women undergoing controlled ovarian stimulation for in vitro fertilization.
Give by SC inj into lower abdominal wall during early to mid-follicular phase; see literature. 3mg once on stimulation day 7, or 0.25mg daily beginning on stimulation day 5 or 6 and continuing until day of hCG administration.
Pregnancy (Cat.X). Nursing mothers.
Do complete gynecological and endocrinological exam first.
Ovarian hyperstimulation syndrome, nausea, headache, inj site reactions, elevated enzymes (eg, ALT, alkaline phosphatase).
Vials 0.25mg (w. diluent)—1
3mg (w. diluent)—1
Psychiatry Advisor Articles
- ADHD, Comorbid Bipolar Disorder Share Similar Neurocognitive Profiles
- Anxiety Prevention Interventions: How Effective Are They?
- Antidepressant Use and Dementia Risk in the Elderly
- No Evidence of Personality Changes Prior to Developing Cognitive Impairment, Dementia
- Sleep Apnea Implant Device Receives FDA Approval
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Duration of Untreated Depression Predicts Depression Severity
- Asenapine Prevents Recurrence of Mood Events in Bipolar Disorder
- Cognitive Dysfunction a Sign of Prodromal Parkinson Disease
- ACOG Update: Marijuana Use Discouraged During Pregnancy, Breastfeeding
- Bipolar Depression Benefits From Midday Bright Light Therapy